Zobrazeno 1 - 10
of 48
pro vyhledávání: '"N. L. Fox"'
Autor:
E. J. Arends, M. Zlei, C. M. Tipton, J. Cotic, Z. Osmani, F. de Bie, S. Kamerling, A. van Maurik, R. Dimelow, Y. I. Gregan, N. L. Fox, T. Rabelink, D. Roth, I. Sanz, J. J. M. van Dongen, C. van Kooten, Y. K. O. Teng
Publikováno v:
Annals of the Rheumatic Diseases. 81:324-325
BackgroundBelimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients with active systemic lupus erythematosus (SLE) and lupus nephritis (LN).1 BEL inh
Autor:
H. Bootsma, S. Arends, L. de Wolff, K. L. Clark, A. van Maurik, P. Mistry, P. Shukla, S. Nihtyanova, N. L. Fox, D. Roth
Publikováno v:
Annals of the Rheumatic Diseases. 81:329.1-330
BackgroundEULAR Sjögren’s syndrome disease activity index (ESSDAI) assesses systemic disease activity in patients (pts) with primary Sjögren’s syndrome (pSS); however, weaknesses include exclusion of patient-reported symptoms, tear and salivary
Autor:
M. A. Petri, G. Bertsias, M. Daniels, N. L. Fox, B. H. Hahn, A. Hammer, J. Harris, H. Quasny, C. Tani, A. Askanase
Publikováno v:
Annals of the Rheumatic Diseases. 81:323.1-323
BackgroundBelimumab (BEL) is approved for the treatment of active autoantibody-positive systemic lupus erythematosus (SLE).1 Four Phase 3 studies have consistently demonstrated greater SLE Responder Index (SRI) response rates with BEL vs placebo (PBO
Autor:
Y. K. O. Teng, A. van Maurik, K. L. Clark, N. L. Fox, Y. I. Gregan, J. Groark, R. Henderson, J. Ocran-Appiah, D. Roth, D. Shanahan, P. P. Tak, C. Aranow
Publikováno v:
Annals of the Rheumatic Diseases. 81:186-186
BackgroundBEL is approved for active SLE and lupus nephritis (adults only). Despite failed trials,1 RTX remains in the SLE treatment armamentarium. Sequential BEL and RTX therapy offers a promising strategy to target B cells by distinct but complemen
Autor:
A Doria, D Bass, A Schwarting, A Hammer, D Gordon, M Scheinberg, N L Fox, J Groark, W Stohl, C Kleoudis, D Roth
Supplemental material for A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus by A Doria, D Bass, A Schwarting, A Hammer, D Gordon, M Scheinberg, NL Fox, J Groark, W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9591e62c0ff1c17756954711e28663
Publikováno v:
Expert Opinion on Biological Therapy. 10:1-18
Agents that activate the TNF-related apoptosis-inducing ligand death receptors, TRAIL-R1 and TRAIL-R2, have attracted substantial attention and investment as potential anti-cancer therapies. Preclinical studies of TRAIL-R agonists indicate that they
Autor:
N. L. Fox, Elisabeth G.E. de Vries, Jaap Verweij, Renée Miceli, Corina N.A.M. Oldenhuis, Walter J. Loos, C. H. Mom, Ferry A.L.M. Eskens, Jourik A. Gietema, Stefan Sleijfer
Publikováno v:
Clinical Cancer Research, 15(17), 5584-5590. AMER ASSOC CANCER RESEARCH
Mom, C H, Verweij, J, Oldenhuis, C N A M, Gietema, J A, Fox, N L, Miceli, R, Eskens, F A L M, Loos, W J, De Vries, E G E & Sleijfer, S 2009, ' Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin : A phase I study ', Clinical Cancer Research, vol. 15, no. 17, pp. 5584-5590 . https://doi.org/10.1158/1078-0432.CCR-09-0996
Clinical Cancer Research, 15(17), 5584-5590. American Association for Cancer Research Inc.
Mom, C H, Verweij, J, Oldenhuis, C N A M, Gietema, J A, Fox, N L, Miceli, R, Eskens, F A L M, Loos, W J, De Vries, E G E & Sleijfer, S 2009, ' Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin : A phase I study ', Clinical Cancer Research, vol. 15, no. 17, pp. 5584-5590 . https://doi.org/10.1158/1078-0432.CCR-09-0996
Clinical Cancer Research, 15(17), 5584-5590. American Association for Cancer Research Inc.
Purpose: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of mapatumumab, a fully human monoclonal antibody targeting tumor necrosis factor–related apoptosis–inducing ligand receptor 1 (TRAIL-R1), in combination with
Autor:
Lucian Miron, M. Ding, Weijing Sun, Matthew Joseph Gribbin, D. Lungulescu, M. Rodriguez-Torres, R.N. Kalyani, R. Humphreys, Igor Bazin, Bruce J. Giantonio, J.L. Egger, Igor Bondarenko, Tudor-Eliade Ciuleanu, Paul Wissel, A. Deptala, N. L. Fox
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(4)
Background This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combin
Autor:
Martin Reck, Matthew Joseph Gribbin, Mircea Dediu, David R. Spigel, Cristina L. Cebotaru, D. Ross Camidge, Robin Humphreys, Jimmie H. Harvey, Joachim von Pawel, N. L. Fox
Publikováno v:
Clinical lung cancer. 15(3)
Background This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIB or stage IV advanced primary NSCLC
Autor:
Martin Reck, J. von Pawel, J. H. Harvey, E Kumm, Gilles Gallant, Mircea Dediu, C. L. Cebotaru, D. R. Camidge, N. L. Fox, David R. Spigel
Publikováno v:
Pneumologie. 65